Protagonist Therapeutics Sees 4.42% Rally, but Fundamentals Remain Weak
Protagonist Therapeutics sees a modest 4.42% rally, yet the stock remains far below its 52‑week high, with no clear breakthrough to sustain the lift.
- PROTAGONIST THERAPEUTICS INC
- United States
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
2 minutes to read